A new study targets resistance by destabilizing the repair system itself
One of the hardest problems in cancer treatment is not the initial response to therapy but what comes after it. Tumors that are vulnerable at first often adapt, restoring the biological functions a drug was designed to exploit. A new study from the Institute for Basic Science and collaborators proposes a different way to attack that problem: instead of trying to outmaneuver resistant tumors through new mutations or new target classes, break the machinery that lets them repair DNA damage in the first place.
The work centers on a small molecule called UNI418. In experiments described in Nature Communications, the researchers found that UNI418 caused substantial reductions in key DNA repair proteins, including RAD51 and CHK1. Without those proteins, cancer cells lost much of their capacity to manage DNA damage efficiently.
Why DNA repair matters in cancer therapy
Many cancer treatments rely, directly or indirectly, on the fact that tumor cells are under constant genomic stress. If enough damage accumulates, the cells die. But tumors survive by activating and restoring repair pathways. One of the most important is homologous recombination, a high-precision mechanism used to fix broken DNA.
That is why therapies such as PARP inhibitors have been effective in certain cancers: they exploit defects in DNA repair. The trouble is that tumors can evolve around those vulnerabilities. Over time, some cancers regain repair capacity and stop responding.
The new study addresses that resilience from a different angle. Instead of focusing mainly on which genes are mutated, the researchers asked whether the repair apparatus could be destabilized at the protein level.
